Trial · NCT04564339
Results by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 80
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections) | IgAN Cohort: Ravulizumab | -41.9 | 95% Confidence Interval -50.2 to -32.0 | percentage change | |
| IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections) | IgAN Cohort: Placebo | -16.8 | 95% Confidence Interval -31.8 to 1.6 | percentage change | |
| LN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections) | LN Cohort: Ravulizumab | -69.7 | 95% Confidence Interval -79.9 to -54.5 | percentage change | |
| LN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections) | LN Cohort: Placebo | -67.0 | 95% Confidence Interval -80.8 to -43.1 | percentage change | |
| IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections) | IgAN Cohort - Ravulizumab | -44.8 | 95% Confidence Interval -55.1 to -32.1 | percentage change | |
| IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections) | IgAN Cohort - Placebo | -45.1 | 95% Confidence Interval -58.0 to -28.4 | percentage change | |
| LN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections) | LN Cohort: Ravulizumab | -77.1 | 95% Confidence Interval -86.0 to -62.4 | percentage change | |
| LN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections) | LN Cohort: Placebo | -75.0 | 95% Confidence Interval -87.2 to -51.2 | percentage change | |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Ravulizumab | Week 26: >30% Reduction | 68.3 | 95% Confidence Interval 51.9 to 81.9 | percentage of participants |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Placebo | Week 26: >30% Reduction | 40.9 | 95% Confidence Interval 20.7 to 63.6 | percentage of participants |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Ravulizumab | Week 26: >50% Reduction | 43.9 | 95% Confidence Interval 28.5 to 60.3 | percentage of participants |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Placebo | Week 26: >50% Reduction | 18.2 | 95% Confidence Interval 5.2 to 40.3 | percentage of participants |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Ravulizumab | Week 50: >30% Reduction | 63.4 | 95% Confidence Interval 46.9 to 77.9 | percentage of participants |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Placebo | Week 50: >30% Reduction | 60.9 | 95% Confidence Interval 38.5 to 80.3 | percentage of participants |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Ravulizumab | Week 50: >50% Reduction | 36.6 | 95% Confidence Interval 22.1 to 53.1 | percentage of participants |
| IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | IgAN Cohort: Placebo | Week 50: >50% Reduction | 39.1 | 95% Confidence Interval 19.7 to 61.5 | percentage of participants |
| LN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | LN Cohort: Ravulizumab | Week 26: >30% Reduction | 50.0 | 95% Confidence Interval 33.4 to 66.6 | percentage of participants |
| LN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | LN Cohort: Placebo | Week 26: >30% Reduction | 73.7 | 95% Confidence Interval 48.8 to 90.9 | percentage of participants |
| LN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | LN Cohort: Ravulizumab | Week 26: >50% Reduction | 47.4 | 95% Confidence Interval 31.0 to 64.2 | percentage of participants |
| LN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections | LN Cohort: Placebo | Week 26: >50% Reduction | 57.9 | 95% Confidence Interval 33.5 to 79.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04564339/results